Electroconvulsive-therapy-associated neutropenia in treatment-resistant schizophrenia: Three case reports

2015 ◽  
Vol 69 (8) ◽  
pp. 504-504
Author(s):  
Hirofumi Tesen ◽  
Hikaru Hori ◽  
Kiyokazu Atake ◽  
Hiroki Beppu ◽  
Jun Nakamura
Keyword(s):  
Electroconvulsive Therapy ◽  
Case Reports ◽  
Treatment Resistant

Combined use of clozapine and ECT: a review

2015 ◽  
Vol 27 (3) ◽  
pp. 131-142 ◽  
Author(s):  
Sandeep Grover ◽  
Nandita Hazari ◽  
Natasha Kate
Keyword(s):  
Electroconvulsive Therapy ◽  
Case Reports ◽  
Case Series ◽  
Side Effect Profile ◽  
Augmentation Therapy ◽  
Treatment Resistant ◽  
Short Term ◽  
Open Label ◽  
Combined Use

ObjectiveThis paper aims to review the available evidence for the use of clozapine and electroconvulsive therapy (ECT) in combination.MethodologyElectronic searches were carried out to identify reports describing the combined use of clozapine and ECT.ResultsForty reports including 208 patients were identified. The majority of reports were in the form of case reports and case series, with few retrospective and open-label studies. The majority of patients were aged between 18 and 65 years and diagnosed with schizophrenia or schizoaffective disorder. Most of the patients refractory to clozapine were started on ECT as an augmentation therapy; however, in some reports, both ECT and clozapine were started concurrently, and in few cases clozapine was started after ECT. In terms of effectiveness, 37.5–100% patients improved in short-term, and sustained long-term improvement (3 weeks to 24 months) was described in few studies. In terms of the side-effect profile, five patients each had delirium and tachycardia and only four patients were described to have prolonged seizures. Overall, the combination was considered effective and safe.ConclusionThere is evidence for the effectiveness and safety of the clozapine–ECT combination and it should be used in patients with treatment-resistant schizophrenia who do not respond to clozapine.

scholarly journals Electroconvulsive therapy in treatment-resistant mania: case reports

2002 ◽  
Vol 57 (1) ◽  
pp. 31-38 ◽  
Author(s):  
Marcia Britto de Macedo Soares ◽  
Ricardo Alberto Moreno ◽  
Doris Hupfeld Moreno
Keyword(s):  
Electroconvulsive Therapy ◽  
Rating Scales ◽  
Rating Scale ◽  
Case Reports ◽  
Large Body ◽  
Treatment Resistant ◽  
Young Mania ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Bipolar Patients

Electroconvulsive therapy is known to be effective in the treatment of mood disorders, more specifically for depression and mania. Although a large body of evidence confirms the efficacy of electroconvulsive therapy in the treatment of mania, few prospective studies have been done to assess its effectiveness in treatment-resistant manic episodes. These case reports describe the initial results of a study that is being conducted to evaluate the efficacy of Electroconvulsive therapy among treatment-resistant bipolar patients. METHODS: Three manic patients (according to DSM-IV criteria) who were considered treatment-resistant underwent a series of 12 bilateral Electroconvulsive therapy sessions. Before the treatment and then weekly, they were evaluated with the following rating scales: Young Mania Rating Scale, Hamilton Rating Scale for Depression, Brief Psychiatric Rating Scale, and Clinical Global Impressions-Bipolar Version. RESULTS: The 3 patients showed a satisfactory response to Electroconvulsive therapy, although some differences in the course of response were observed. CONCLUSION: These case reports suggest that Electroconvulsive therapy needs further evaluation for the treatment of resistant bipolar patients.

A Pilot Study of Switching Electroconvulsive Therapy for Patients With Treatment Resistant Schizophrenia or Mood Disorder

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Xiao Wei Tan ◽  
Li Keat Oon ◽  
Yun Ying Tammy Tsang ◽  
Hatta Santoso Ong ◽  
Phern Chern Tor
Keyword(s):  
Pilot Study ◽  
Mood Disorder ◽  
Electroconvulsive Therapy ◽  
Treatment Resistant

Ketamine Infusions for Complex Regional Pain Syndrome

2016 ◽  
Author(s):  
Roy K. Esaki
Keyword(s):  
Chronic Pain ◽  
Complex Regional Pain Syndrome ◽  
Hepatic Dysfunction ◽  
Case Reports ◽  
Pain Syndrome ◽  
Nmda Receptor Antagonist ◽  
Treatment Resistant ◽  
Urinary Tract Symptoms ◽  
Chronic Pain Conditions ◽  
Lower Urinary

Ketamine is an N-methyl-d-aspartate (NMDA) receptor antagonist that has been increasingly used in the management of treatment-resistant chronic pain conditions, particularly representing neuropathic involvement or central sensitization. Complex regional pain syndrome (CRPS) is a prototypical condition often treated with ketamine infusions. Although the analgesic benefits of ketamine as an opioid-sparing adjunct in the preoperative period have been well studied, the use of ketamine to mitigate chronic pain conditions remains largely anecdotal, composed largely of case reports and uncontrolled small studies. The limited evidence and published reports support the use of ketamine infusions as one aspect of a comprehensive, multimodal approach for CRPS. Although ketamine infusions are relatively safe when titrated appropriately, with minimal respiratory depression, side effects include sympathetic activation, unpleasant psychomimetic effects, lower urinary tract symptoms, and hepatic dysfunction. 

Sign in / Sign up

Export Citation Format

Share Document